Clinical trials: Sitagliptin, completed
Diabetes
Treatment of Latent Autoimmune Diabetes of the Adult
The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.
- Trial name
- LADA (NCT01140438)
- Testing
- metformin+ NPH insulin, metformin + sitagliptin +/- repaglinide
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Norwegian University of Science and Technology
Type 2 Diabetes
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.
- Trial name
- CMAS (NCT02173457)
- Testing
- Chiglitazar, Sitagliptin
- Where
- 37 sites in China
- Volunteers
- 740 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Non-alcoholic Fatty Liver Disease
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of liver disease that can lead to cirrhosis and liver-related…
- Trial name
- NCT01963845
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes…
- Trial name
- NCT00700817
- Testing
- liraglutide, sitagliptin, metformin
- Where
- 166 sites in United States, Canada and 13 more
- Volunteers
- 665 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes
This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT01517321
- Testing
- MK-0431/ONO-5435
- Where
- 6 sites in Japan
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is ≥ 7.5% with sulfonylurea and…
- Trial name
- NCT03076112
- Testing
- Ipragliflozin, Sitagliptin
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy.
- Trial name
- NCT01490918
- Testing
- Acarbose
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- The Catholic University of Korea
Type 2 Diabetes Mellitus
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
- Trial name
- NCT01933672
- Testing
- PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pfizer
Type 2 Diabetes
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01845831
- Testing
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin
- Where
- 5 sites in United States
- Volunteers
- 292 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
This study will evaluate the efficacy and safety of 100 mg DRBP108 tablets in the treatment of type 2 diabetes mellitus. A total of 750 subjects will be randomly allocated to three groups: DRBP108, active comparator and placebo…
- Trial name
- NCT04161430
- Where
- 2 sites in China
- Volunteers
- 766 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
Incretin-based Drugs and the Risk of Heart Failure
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure…
- Trial name
- NCT02456428
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,499,650 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Healthy
Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study
Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the hypoglycemic activity of DPP4, but there is…
- Trial name
- NCT01820104
- Testing
- lansoprazole, 30 mg per day for 6 days
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Type 2 Diabetes Mellitus
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
This is a multi-center, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with Type 2 diabetes mellitus (DM) who have been treated with sulphonylurea (SU)…
- Trial name
- NEEDS (NCT01285076)
- Testing
- Other: Retrospective chart review; one participant encounter visit.
- Where
- Taiwan
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
This phase II, multicenter, randomized, double-blind, double-dummy study with four parallel treatment groups, with active control, will be performed only in brazilian sites under the sponsorship of Eurofarma Laboratórios S.A..
- Trial name
- EVOLUTION (NCT02689362)
- Testing
- Evogliptin, Sitagliptin
- Where
- 10 sites in Brazil
- Volunteers
- 146 people
- Sponsor
- Eurofarma Laboratorios S.A.
Diabetes
Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis
Objective: To assess the effect if co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic'…
- Trial name
- NCT00683735
- Testing
- Sitagliptin, Metformin
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Michael A. Nauck
Diabetes Mellitus Type 2
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.
- Trial name
- FPG-VISIT (NCT01398592)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 15 sites in Germany
- Volunteers
- 187 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction, Unstable Angina Pectoris
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
A three months, double-blind, randomised, parallel-group study evaluating the efficacy of sitagliptin (Januvia™) versus placebo on beta-cell function in patients with newly detected glucose abnormalities and acute myocardial…
- Conditions
- Myocardial Infarction, Unstable Angina Pectoris, Diabetes Mellitus, Impaired Glucose Tolerance
- Trial name
- BEGAMI (NCT00627744)
- Testing
- Sitagliptin
- Where
- 2 sites in Sweden
- Volunteers
- 85 people
- Sponsor
- Karolinska Institutet
Type 2 Diabetes
Study of Sulphonylurea Synergy With DPP4 Inhibitors
The Study of Sulphonylurea Synergy with DPP4 Inhibitors (SSS Study) will establish whether a very low dose of sulphonylurea will have a synergistic role on augmentation of insulin secretion when given in combination with a DPP4…
- Trial name
- SSS (NCT04192292)
- Testing
- Sulfonylurea, DPP4 Inhibitor
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Dundee
Healthy
DPP4 Inhibition & Beta Cell Function
This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting…
- Trial name
- NCT02683187
- Testing
- Active Comparator: Sitagliptin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.